antibody-drug conjugate; cell therapies; clinical trials; covid-19; drug delivery; gene therapy; mergers and acquisitions; product approvals; rare diseases; targeted therapeutics; acute myeloid leukemia/dt [Drug Therapy]; Alzheimer disease/dt [Drug Therapy]; angioneurotic edema/dt [Drug Therapy]; article; atherosclerosis/dt [Drug Therapy]; atopic dermatitis/dt [Drug Therapy]; autism/dt [Drug Therapy]; B cell lymphoma/dt [Drug Therapy]; chronic obstructive lung disease/dt [Drug Therapy]; coronavirus disease 2019/dt [Drug Therapy]; coronavirus disease 2019/pc [Prevention]; cytomegalovirus infection/dt [Drug Therapy]; degenerative disease/dt [Drug Therapy]; diffuse large B cell lymphoma/dt [Drug Therapy]; drug approval; drug design; endocrine ophthalmopathy/dt [Drug Therapy]; endometrium cancer/dt [Drug Therapy]; Fabry disease/dt [Drug Therapy]; familial hypercholesterolemia/dt [Drug Therapy]; fibrosing alveolitis/dt [Drug Therapy]; follicular lymphoma/dt [Drug Therapy]; glaucoma/dt [Drug Therapy]; human; Human immunodeficiency virus infection/dt [Drug Therapy]; hypoxic ischemic encephalopathy/dt [Drug Therapy]; inflammatory bowel disease/dt [Drug Therapy]; influenza A/dt [Drug Therapy]; intraocular hypertension/dt [Drug Therapy]; large cell lymphoma/dt [Drug Therapy]; Lennox Gastaut syndrome/dt [Drug Therapy]; marginal zone lymphoma/dt [Drug Therapy]; multiple sclerosis/dt [Drug Therapy]; myasthenia gravis/dt [Drug Therapy]; myelodysplastic syndrome/dt [Drug Therapy]; myelooptic neuropathy/dt [Drug Therapy]; non insulin dependent diabetes mellitus/dt [Drug Therapy]; non small cell lung cancer/dt [Drug Therapy]; nonhodgkin lymphoma/dt [Drug Therapy]; obesity/dt [Drug Therapy]; presbyopia/dt [Drug Therapy]; priority journal; psoriasis/dt [Drug Therapy]; psoriasis vulgaris/dt [Drug Therapy]; psoriatic arthritis/dt [Drug Therapy]; schizophrenia/dt [Drug Therapy]; severe myoclonic epilepsy in infancy/dt [Drug Therapy]; spasticity/dt [Drug Therapy]; systemic lupus erythematosus/dt [Drug Therapy]; tuberous sclerosis; ulcerative colitis/dt [Drug Therapy]; United States; adeno associated virus vector; antivirus agent/dv [Drug Development]; antivirus agent/dt [Drug Therapy]; apremilast/dv [Drug Development]; apremilast/dt [Drug Therapy]; atuzaginstat/dv [Drug Development]; atuzaginstat/dt [Drug Therapy]; batoclimab/dv [Drug Development]; batoclimab/dt [Drug Therapy]; benzimidavir/dv [Drug Development]; benzimidavir/dt [Drug Therapy]; betibeglogene autotemcel/dv [Drug Development]; betibeglogene autotemcel/dt [Drug Therapy]; cannabidiol/cb [Drug Combination]; cannabidiol/dv [Drug Development]; cannabidiol/dt [Drug Therapy]; cannabidiol/pv [Special Situation for Pharmacovigilance]; cannabidivarin/cb [Drug Combination]; cannabidivarin/dv [Drug Development]; cannabidivarin/dt [Drug Therapy]; cannabinoid/dt [Drug Therapy]; cannabinoid/pv [Special Situation for Pharmacovigilance]; clobazam/cb [Drug Combination]; clobazam/dv [Drug Development]; clobazam/dt [Drug Therapy]; clobazam/pv [Special Situation for Pharmacovigilance]; crisaborole/dv [Drug Development]; crisaborole/dt [Drug Therapy]; deucravacitinib/dv [Drug Development]; deucravacitinib/dt [Drug Therapy]; dostarlimab/dv [Drug Development]; dostarlimab/dt [Drug Therapy]; enzyme inhibitor/dv [Drug Development]; evinacumab/dv [Drug Development]; evinacumab/dt [Drug Therapy]; foralumab/dv [Drug Development]; foralumab/dt [Drug Therapy]; fostemsavir/dv [Drug Development]; fostemsavir/dt [Drug Therapy]; inebilizumab/dv [Drug Development]; inebilizumab/dt [Drug Therapy]; kallikrein inhibitor/dv [Drug Development]; kallikrein inhibitor/dt [Drug Therapy]; lisocabtagene maraleucel/dv [Drug Development]; lisocabtagene maraleucel/dt [Drug Therapy]; nabiximols/dv [Drug Development]; nabiximols/dt [Drug Therapy]; ozanimod/dv [Drug Development]; ozanimod/dt [Drug Therapy]; peginterferon beta1a/dv [Drug Development]; peginterferon beta1a/dt [Drug Therapy]; pilocarpine/dv [Drug Development]; pilocarpine/dt [Drug Therapy]; promethazine; roflumilast/dv [Drug Development]; roflumilast/dt [Drug Therapy]; SARS-CoV-2 vaccine/dv [Drug Development]; SARS-CoV-2 vaccine/dt [Drug Therapy]; semaglutide/dv [Drug Development]; semaglutide/dt [Drug Therapy]; sotorasib/dv [Drug Development]; sotorasib/dt [Drug Therapy]; sotrovimab/dv [Drug Development]; sotrovimab/dt [Drug Therapy]; tepotinib/dv [Drug Development]; tepotinib/dt [Drug Therapy]; tirzepatide/dv [Drug Development]; tirzepatide/dt [Drug Therapy]; umbralisib/dv [Drug Development]; umbralisib/dt [Drug Therapy]; unclassified drug; voxeralgagene autotemcel/dv [Drug Development]; voxeralgagene autotemcel/dt [Drug Therapy]; ziritaxestat/dv [Drug Development]; ziritaxestat/dt [Drug Therapy]; zorecimeran/dv [Drug Development]; zorecimeran/dt [Drug Therapy]; breyanzi; evkeeza; gwp 42003/cb [Drug Combination]; gwp 42003/dt [Drug Therapy]; gwp 42003/pv [Special Situation for Pharmacovigilance]; kvd 900/dv [Drug Development]; kvd 900/dt [Drug Therapy]; mrna 1273 351/dv [Drug Development]; mrna 1273 351/dt [Drug Therapy]; ozembic; r 552/dv [Drug Development]; r 552/dt [Drug Therapy]; tak 620; tepmetko; ukoniq; vir 2482/dv [Drug Development]; vir 2482/dt [Drug Therapy]; vir 7832/dv [Drug Development]; vir 7832/dt [Drug Therapy]